The Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services have announced that the U.S. Government has reached an agreement in principle on pharmaceutical pricing with the United Kingdom.
In the U.S.-U.K. Economic Prosperity Deal, President Donald Trump and Prime Minister Keir Starmer agreed to address long-standing imbalances in bilateral pharmaceutical trade by improving the overall environment for pharmaceutical companies operating in the United Kingdom.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Joji Xavier
For comments and feedback: contact editorial@rttnews.com